Phase III results suggest Bayer’s elinzanetant has a safety and efficacy advantage over its Astellas rival in reducing hot flashes, but investors are still not convinced the drug will be a blockbuster.
Bayer looks to have an edge over an established rival with elinzanetant, its soon-to-be-filed drug for menopause-related hot flashes, with full data readouts from two Phase III studies bolstering its profile. However, investors remain skeptical about its purported blockbuster prospects.
Elinzanetant is one of a few late-stage drugs that Bayer is relying on to help stabilize its pharma division sales...
The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Series B cash will be used to advance its Stargardt disease gene therapy.
